← All trials
NCT06023459
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2024
- Primary completion
- Nov 30, 2024
- Completion date
- Dec 30, 2024
- First posted
- Sep 5, 2023
- Last posted
- Sep 5, 2023
- Enrollment
- 144
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, Los AngelesLead sponsor
- Cornell UniversityCollaborator
- National Institute on Drug Abuse (NIDA)Collaborator
- National Institutes of Health (NIH)Collaborator
- Oregon Health and Science UniversityCollaborator
- RAND CorporationCollaborator
- The EMMES CorporationCollaborator
- University of Illinois at ChicagoCollaborator
- University of WashingtonCollaborator
- West Virginia UniversityCollaborator
- University of California, Los AngelesOfficial
- University of California, Los AngelesCollaborator
- University of California, Los AngelesSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.